SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study.

Camm, AJ; Amarenco, P; Haas, S; Bach, M; Kirchhof, P; Kuhls, S; Lambelet, M; Turpie, AGG; XANTUS Investigators (2020) Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study. Clin Cardiol, 43 (12). pp. 1405-1413. ISSN 1932-8737 https://doi.org/10.1002/clc.23452
SGUL Authors: Camm, Alan John

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

BACKGROUND: The XANTUS study (NCT01606995) demonstrated low rates of stroke and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in clinical practice for the prevention of thromboembolic events (N = 6784). HYPOTHESIS: Because previous real-world studies have not reported gender-dependent responses to rivaroxaban treatment, this sub-analysis of the XANTUS study investigated the effect of gender on outcomes. METHODS: The centrally adjudicated outcomes were compared between genders. Primary outcomes were major bleeding and all-cause death. Secondary outcomes included symptomatic thromboembolic events. Multivariable Cox regression analysis was performed to assess the effect of risk factors on outcomes between genders. RESULTS: A total of 2765 female and 4016 male patients were included in the analysis. Baseline characteristics were generally similar. No nominally significant interaction between gender and risk factors for the study outcomes was observed. Rates of major bleeding, all-cause death and symptomatic thromboembolic events in patients with non-valvular AF receiving rivaroxaban for stroke prevention were similar in men and women; no significant differences in risk factors for these outcomes were observed between genders. CONCLUSIONS: Further research is needed to better characterize the relative importance of different risk factors on outcomes in men vs women and to determine whether gender differences exist in patients treated with non-vitamin K antagonist oral anticoagulants.

Item Type: Article
Additional Information: © 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: anticoagulant, atrial fibrillation, real-world evidence, stroke, XANTUS Investigators, Cardiovascular System & Hematology, 1102 Cardiorespiratory Medicine and Haematology
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Clin Cardiol
ISSN: 1932-8737
Language: eng
Dates:
DateEvent
8 December 2020Published
8 September 2020Published Online
6 August 2020Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
UNSPECIFIEDBayerUNSPECIFIED
UNSPECIFIEDJanssen Research and DevelopmentUNSPECIFIED
PubMed ID: 32896928
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/112391
Publisher's version: https://doi.org/10.1002/clc.23452

Actions (login required)

Edit Item Edit Item